Sector News

AZ signs deal with Europe’s IVA for coronavirus vaccine supply

June 16, 2020
Life sciences

AstraZeneca has agreed with Europe’s Inclusive Vaccines Alliance (IVA) that it will supply up to 400 million doses of the University of Oxford’s COVID-19 vaccine to broaden access in the region.

The deal, which will see deliveries start by the end of this year, allows the IVA aims to accelerate the supply of the vaccine and to make it available to other European countries that wish to participate in the initiative.

“This agreement will ensure that hundreds of millions of Europeans have access to Oxford University’s vaccine following approval,” said Pascal Soriot, AZ’ chief executive.

“With our European supply chain due to begin production soon, we hope to make the vaccine available widely and rapidly. I would like to thank the governments of Germany, France, Italy and the Netherlands for their commitment and swift response.”

AstraZeneca is currently working on establishing a number of supply chains in parallel across the world, including for Europe, with total manufacturing capacity currently at two billion doses.

Oxford University has recently begun testing AZD1222 in a Phase II/III UK trial involving around 10,000 adult volunteers, and other late-stage trials are due to begin in a number of countries.

By: Selina McKee

Source: Pharma Times

Related News

October 17, 2020

Ong leaves Biogen to become CEO-partner at Flagship

Life sciences

The appointment makes Tuyen Ong the latest in a series of new CEO-partners hired by Flagship. Flagship Pioneering has named Tuyen Ong as CEO-partner. The new role sees the ex-Biogen […]

October 17, 2020

Pharma, take note: Millennials plan to spend more on meds, study says

Life sciences

The COVID-19 pandemic has millennials worried—and that has them planning to buy more prescription drugs in the future, new research finds. WPP’s global media group, Mindshare, began surveying consumers in […]

October 17, 2020

AstraZeneca secures $486m from US for Covid-19 antibody

Life sciences

AstraZeneca has received an investment of approximately $486m from the US Government to develop and supply its long-acting antibody (LAAB) cocktail, AZD7442, for Covid-19 treatment. AstraZeneca has received an investment […]